AGPAT2
1-acyl-sn-glycerol-3-phosphate acyltransferase beta
Protein Summary
Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
- ENST00000371694
- ENSP00000360759
- ENSG00000169692
- ENST00000371696
- ENSP00000360761
- ENST00000538402
- ENSP00000438919
- BSCL
- BSCL1
- LPAAB
- 1-AGPAT2
- LPAAT-beta
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.8 | ||
kinase perturbation | 0.71 | ||
disease perturbation | 0.68 | ||
cellular component | 0.67 | ||
PubMedID | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 100.83 (req: < 5)
Gene RIFs: 25 (req: <= 3)
Antibodies: 164 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 100.83 (req: >= 5)
Gene RIFs: 25 (req: > 3)
Antibodies: 164 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 78
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0